M
MohdZai
Iron
- Joined
- Jun 10, 2026
- Posts
- 9
- Reputation
- 4
People often claim of Erdas effects on brain function, but I think it's partly misunderstood. A ley factor of the brain studies is recognizing erda is typically used after chemotherapy. When examined they noted that it was used after 1-2 prior lines of therapy.
"In the phase 3 THOR study, patients with advanced or metastatic bladder cancer with FGFR3/2 alterations who had progressed on or after 1–2 prior lines of therapy (including anti‑PD‑(L)1) were randomized."
Chemotherapy is a known cognitive function killer, with a stereotype of "chemo brain." This is caused by the neuroinflammation that is caused by chemo due to the negation of all growing cells. Some of these effects are seen to be temporary, while others are examined longterm, and most likely dependent on the number of rounds, a patient has went through chemo for. Erdafinitib has shown anti neuroinflammatory pathways in mice.
"In BV2 microglial cells, erdafitinib pretreatment significantly reduced the increases in proinflammatory cytokines, NLRP3 inflammasome activation and JNK/PLCγ signaling induced by LPS. In C57BL6/N mice, erdafitinib pretreatment significantly suppressed LPS-stimulated microglial/astroglial activation and proinflammatory cytokine expression."
Willing to hear out responses regarding potential brain effects since it targets FGFR1-4.
"In the phase 3 THOR study, patients with advanced or metastatic bladder cancer with FGFR3/2 alterations who had progressed on or after 1–2 prior lines of therapy (including anti‑PD‑(L)1) were randomized."
Chemotherapy is a known cognitive function killer, with a stereotype of "chemo brain." This is caused by the neuroinflammation that is caused by chemo due to the negation of all growing cells. Some of these effects are seen to be temporary, while others are examined longterm, and most likely dependent on the number of rounds, a patient has went through chemo for. Erdafinitib has shown anti neuroinflammatory pathways in mice.
"In BV2 microglial cells, erdafitinib pretreatment significantly reduced the increases in proinflammatory cytokines, NLRP3 inflammasome activation and JNK/PLCγ signaling induced by LPS. In C57BL6/N mice, erdafitinib pretreatment significantly suppressed LPS-stimulated microglial/astroglial activation and proinflammatory cytokine expression."
Willing to hear out responses regarding potential brain effects since it targets FGFR1-4.